trastuzumab-pkrb Herzuma
Selected indexed studies
- Trastuzumab. (, 2006) [PMID:29999639]
- Clinical development of CT-P6 in HER2 positive breast cancer. (Expert Opin Biol Ther, 2019) [PMID:31507219]
- A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. (Cancer, 2023) [PMID:37246414]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trastuzumab. (2006) pubmed
- Clinical development of CT-P6 in HER2 positive breast cancer. (2019) pubmed
- A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. (2023) pubmed
- Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18. (2023) pubmed
- Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis. (2022) pubmed
- Targeting human EGFR 2 (HER2) in salivary gland carcinoma. (2023) pubmed
- Safety and Efficacy of Anti-Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review. (2025) pubmed
- Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). (2023) pubmed
- Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. (2021) pubmed
- Challenges with effective removal of surfactants from monoclonal antibody formulations. (2025) pubmed